

In the Claims

1-62 (canceled)

63 (currently amended). Anastrozole oxalate, wherein said anastrozole oxalate exhibits the following crystal parameters: $a = 5.6514(8) \text{ \AA}$, $b = 32.718(5) \text{ \AA}$, $c = 10.7384(17) \text{ \AA}$, and $\beta = 101.652(4) \text{ degrees}$.

64 (previously presented). The anastrozole oxalate of claim 63, wherein said anastrozole oxalate is crystalline.

65 (previously presented). The anastrozole oxalate of claim 63, wherein said anastrozole oxalate exhibits a monoclinic crystal system.

66 (previously presented). The anastrozole oxalate of claim 63, wherein said anastrozole oxalate exhibits a Cc space group.

67 (canceled).

68 (previously presented). The anastrozole oxalate of claim 63, wherein said anastrozole oxalate is characterized by a melting point at about 164-166 degrees C.

69 (currently amended). A pharmaceutical dosage form comprising a therapeutically effective amount of anastrozole oxalate according to claim 63.

70 (currently amended). A method for treating a subject with breast cancer, comprising administering to said subject a therapeutically effective amount of anastrozole oxalate according to claim 63.